Myriad Genetics
MYGN
228 hedge funds and large institutions have $833M invested in Myriad Genetics in 2025 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 79 increasing their positions, 79 reducing their positions, and 29 closing their positions.
402% more call options, than puts
Call options by funds: $854K | Put options by funds: $170K
28% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 29
3% more funds holding
Funds holding: 221 → 228 (+7)
1.26% more ownership
Funds ownership: 101.59% → 102.85% (+1.3%)
0% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 79
34% less capital invested
Capital invested by funds: $1.27B → $833M (-$436M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
+$26.1M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.36M |
| 3 |
D.E. Shaw & Co
New York
|
+$8.44M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$6.6M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$5.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$17M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$9.01M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$5.88M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$5.6M |
| 5 |
BlackRock
New York
|
-$5.4M |
MYGN Hedge Fund Activity: Q1 2025 in Review
228 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2025, worth a combined $833M — down 34% from $1.27B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new MYGN positions and 29 closed out — a net gain of 8 holders — while 79 added to existing stakes and 79 trimmed.
The largest buyer was Disciplined Growth Investors, adding an estimated $26.1M. The largest seller was Wellington Management Group, cutting an estimated $17M.
- 228 institutional investors held Myriad Genetics (MYGN) as of Q1 2025, up from 221 in Q4 2024.
- Funds reported $833M of Myriad Genetics stock for Q1 2025, down 34% quarter-over-quarter.
- 37 funds opened new Myriad Genetics positions in Q1 2025 and 29 closed out, a net change of +8 holders.
- The largest Myriad Genetics buyer in Q1 2025 was Disciplined Growth Investors, an estimated $26.1M added.
- The largest Myriad Genetics seller in Q1 2025 was Wellington Management Group, an estimated $17M sold.
Based on aggregated 13F filings for Q1 2025.